SELLAS Life Sciences Group, Inc. SLS R2K
Company Overview
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +576.26% |
| 6 Months: | +286.99% |
| 3 Months: | +181.30% |
| 1 Month: | +72.77% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SLS SELLAS Life Sciences Group, Inc. R2K | 13.39 | -58.22 | $2.63B | 0.00% | -39.64% | -43.59% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 5.70M | 1.90M | 0 | 1.00M | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - |
| Gross Profit | 2.91M | 1.45M | 1.23M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -7.99M | -6.89M | - | -11.85M | -15.78M | -10.57M | -8.91M | -9.08M | -8.63M | -8.97M | -9.29M | -6.47M | -5.09M | -4.91M | -4.46M | - | - | - | - | - | - | -4.06M | -4.27M | -4.49M | -2.25M | -4.45M | -6.98M | -16.73M | -8.62M | -7.15M | -11.28M | -9.05M | -9.36M | -9.64M | -7.62M | -7.33M | -6.06M | -6.87M | -7.08M | -9.25M |
| Net Income | 5.39M | -6.93M | -5.52M | -2.54M | -19.94M | -6.17M | -10.54M | -15.66M | -18.03M | -16.49M | 5.39M | -6.93M | -4.60M | -5.91M | -4.46M | -8.00M | -6.06M | -290.00K | -4.54M | -3.13M | -4.20M | -4.14M | -4.42M | -4.47M | -2.40M | -4.61M | -7.08M | -16.74M | -8.41M | -7.02M | -11.10M | -8.84M | -9.27M | -9.57M | -7.47M | -7.11M | -5.81M | -6.60M | -6.79M | -8.41M |
| Diluted EPS | -0.11 | - | - | - | - | - | - | - | - | - | 0.58 | - | - | -0.22 | - | - | - | - | - | - | - | - | -0.66 | -0.53 | -0.16 | -0.30 | -0.45 | -1.05 | -0.41 | -0.34 | -0.47 | -0.31 | -0.33 | -0.21 | -0.13 | -0.10 | -0.07 | -0.07 | -0.06 | -0.05 |
| R&D Expense | 5.28M | 3.63M | - | 6.77M | 8.07M | 7.03M | 5.83M | 7.20M | 5.74M | 5.44M | 6.17M | 3.62M | 2.18M | 1.83M | 1.07M | 1.80M | 1.59M | 1.72M | 1.86M | 1.38M | 1.80M | 1.86M | 2.28M | 2.37M | 4.28M | 3.46M | 4.54M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 2.49M | 9.32M | - | - | - | - | 0 | 1.90M | 7.60M | 1.00M | 0 | - | - |
| Operating Income | - | -12.49M | -21.20M | -28.49M | -43.90M | -34.22M | -15.99M | -23.04M | - | -20.04M | -16.98M | -25.29M | -41.95M | -37.87M | -31.51M | -28.27M |
| Net Income | -11.99M | -11.48M | -34.97M | -76.68M | -36.61M | -63.90M | -17.68M | -23.75M | -27.67M | -19.29M | -16.76M | -20.70M | -41.30M | -37.34M | -30.88M | -26.86M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -2.11 | -1.34 | -2.13 | -1.34 | -0.50 | -0.25 |
| R&D Expense | 7.87M | 3.85M | 14.61M | - | - | - | 11.39M | 6.07M | 8.77M | 7.29M | 9.28M | 15.67M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.48M | 30.97M | 54.99M | 87.98M | 80.49M | 82.14M | 6.42M | 33.53M | 16.91M | 16.61M | 46.05M | 26.27M | 20.94M | 6.22M | 19.43M | 78.34M |
| Total Equity | - | 2.43M | 10.11M | 27.76M | 5.89M | 37.06M | -12.26M | -5.00M | 2.07M | 5.25M | 6.09M | 27.96M | 20.35M | 4.85M | -7.98M | 9.46M | 70.87M |
| Cash & Equivalents | 5.68M | 6.89M | 47.79M | 32.81M | 47.79M | 23.65M | 1.40M | 5.96M | 2.32M | 5.34M | 7.28M | 35.30M | 21.36M | 17.12M | 2.53M | 13.89M | 71.79M |
| Long Term Debt | - | - | - | 0 | 7.74M | 4.49M | 0 | - | 2.61M | 0 | - | - | - | - | - | - | - |
| Total Liabilities | - | 5.05M | 20.86M | 27.23M | 82.09M | 43.43M | 68.63M | 11.42M | 31.46M | 11.67M | 10.52M | 18.09M | 5.93M | 16.09M | 14.20M | 9.97M | 7.47M |
| Current Liabilities | - | 5.03M | 11.20M | 15.92M | 62.47M | 27.23M | 57.07M | 5.76M | 24.57M | 5.97M | 5.29M | 12.34M | 4.98M | 15.52M | 13.73M | 9.51M | 7.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.26M | -14.67M | -20.97M | -28.93M | -42.87M | -48.16M | -11.85M | -10.99M | -30.42M | -17.64M | -10.42M | -26.02M | -23.81M | -31.41M | -35.40M | -28.39M |
| Investing Cash Flow | -106.00K | 14.00K | -87.00K | -12.04M | -5.53M | 10.39M | -85.00K | 12.16M | 0 | - | - | 0 | -4.50M | -5.50M | 0 | - |
| Financing Cash Flow | 11.57M | 19.20M | 42.43M | 55.95M | 24.26M | 43.84M | 16.50M | 5.53M | 23.12M | 19.57M | 38.44M | 12.07M | 24.08M | 22.32M | 46.76M | 86.30M |
| Capital Expenditure | -106.00K | -53.00K | - | -320.00K | -57.00K | -153.00K | -6.00K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -10.36M | -14.72M | - | -29.25M | -42.93M | -48.31M | -11.86M | - | - | - | - | - | - | - | - | - |
| Share Buybacks | 3.85M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - | - | - | 0 | 487.00K | 0 | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -1,145.5% | -471.1% | - | - | - | - | - | -893.8% | -332.8% | -4,195.0% | - | - | - |
| Net Margin % | - | - | - | -3,083.2% | -392.8% | - | - | - | - | - | -881.9% | -272.4% | -4,130.1% | - | - | - |
| ROE % | -493.5% | -113.6% | -126.0% | -1,302.7% | -98.8% | 521.1% | 353.8% | -1,147.5% | -527.6% | -316.6% | -59.9% | -101.7% | -851.4% | 468.2% | -326.3% | -37.9% |
| ROCE % | - | -63.2% | -54.3% | -111.7% | -82.4% | -136.5% | -2,415.1% | -257.2% | - | -177.1% | -50.4% | -118.8% | -772.8% | 503.8% | -317.6% | -39.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 6.20% | 12.20M | $172.42M |
| 2 | State Street Corporation | 4.27% | 8.40M | $118.68M |
| 3 | Vanguard Capital Management LLC | 3.83% | 7.53M | $106.38M |
| 4 | Geode Capital Management, LLC | 1.99% | 3.91M | $55.30M |
| 5 | Marshall Wace LLP | 1.04% | 2.04M | $28.80M |
| 6 | Jones Financial Companies, L.L.L.P. | 0.85% | 1.68M | $23.68M |
| 7 | Vanguard Portfolio Management LLC | 0.74% | 1.46M | $20.68M |
| 8 | Morgan Stanley | 0.68% | 1.34M | $18.89M |
| 9 | Northern Trust Corporation | 0.65% | 1.28M | $18.04M |
| 10 | Vanguard Fiduciary Trust Co | 0.61% | 1.20M | $17.00M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLS
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdWdUTGlHV1d4azVKbUhkX2JCSHl0QXFmY2F1Q2RfQ3BsaVlTOTU4NVRwUVE0UlZsYXBNVEtkR3pOMGk0SmNqYy1VdnBSV0w3bHlTYk54N3BQRVREMnh2bWZiSHpNSDZfdXlIWXNlZUdUeHFPTVFUd3ZEWHR0aUNFNmV6bkM4emZmbGZlZ3…
SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxOVTVxckJTa0s3TWNaTGN0M1ZzaDU2MmhkR1hjV3pIbVZwNGptOUVqYXI3SF9tcXBZQTBSeHNGSzhYWHkwSnVpOUxsd3A4U3FJaHZsclgycGNJNEpzSHVsVTN2XzJpZzBxT2NvXzZnVlVOYkZuejFFZ1doMWVDM0NfQWxjdFRqLW11SHlEbD…
SLS Stock Jumps Overnight After New Investor Disclosure – Retail Flags ‘Massive’ Options Bet Ahead Of AML Data - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQeTlpVkxaajdPWHlTZHB4X1FHQ2tnbEdkcGxsTjNzY0JLRnNIb3Fta2tRcGRGdzNxSHhHYjlhZkdVTlZGUTIzYUFCVnI0MWR0dVRFakdBTGRWT2pZbjdXNFczeGtUcE4xRG1jd3hwNUt5d2dLRmpPdW1XZDM1ak9NeERiZVZ0S1pMWXZxNz…
Here’s Why SELLAS (SLS) is Among the 10 Best Performing American Stocks in June 2026 - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQUkpfTVg3UWtMUmJwcF9ib2ptOF8tNHNmbXJaZ0Z1U2FzVHdON09waldpV1o4cVpiQnRvZ1dWZ3JMQkRIUDVqOWllLTVQZHF0YmxHUlNfZFVKaUZDRUp5SGRlN0tDTjRaR0lqQm95SEx1UVAxeWMxTVJhTTBLOWpqSUJuTmNsZ0gwZXpjb3…
SELLAS Life Sciences Group (SLS) Stock Looks Above Fair Value Before Key Trial Data - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQbmZUMlkySG5hc3o5UHhtUTlBQ0NYOV9wTVJReFFxMEplNHNGRXBOUGd5dWdjdkxZejI2a1dUTko0Ylp5emRsNHJkZlExSGphd3JuYjJBT21qU1E3dFBhc2FYLVMtUkk2aGVXOVFrM3dqSzBSWEVrYTFOVnRTOWZQM3oxQ0tXZlBhLWM5Zm…
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPSkdLNjN2dmcwOTNfUnVXanFFOEJwd3hWSEpzVkxrXzdzYlhienYxS0tYRUVTNHYzRW9fd0k0SzBRT2RiTVZWdFpjZ0F6V0Y2d3dNblFpQkNZVmFrQlk4Y0cyeVE4U2tVckMzT1N2RjhTZnpFd3BqY19GdThCQXI1alZaZGpsTjRMdkVyRl…
SLS — Frequently Asked Questions
What is the current share price of SELLAS Life Sciences Group, Inc. (SLS)?
As of 2026-07-14 21:23 PDT, SELLAS Life Sciences Group, Inc. (SLS) trades at $13.39 on NasdaqCM. Its 52-week range is $1.39 to $15.45.
What is the market capitalisation of SLS?
SELLAS Life Sciences Group, Inc. (SLS) has a market capitalisation of $2.63B on NasdaqCM.
What is the P/E ratio of SLS?
SLS trades at a trailing price-to-earnings (P/E) ratio of -58.22. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 13.23.
What is the return on equity (ROE) of SLS?
SLS has a return on equity (ROE) of -43.59%. Its return on capital employed (ROCE) is -39.64%.
Is SLS a good stock to buy?
This page provides a data-driven analysis of SELLAS Life Sciences Group, Inc. (SLS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.